Viking Therapeutics Inc - Asset Resilience Ratio
Viking Therapeutics Inc (VKTX) has an Asset Resilience Ratio of 75.44% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Viking Therapeutics Inc's Asset Resilience Ratio has changed over time. Check how strategically is Viking Therapeutics Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Viking Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see VKTX market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $539.93 Million | 75.44% |
| Total Liquid Assets | $539.93 Million | 75.44% |
Asset Resilience Insights
- Very High Liquidity: Viking Therapeutics Inc maintains exceptional liquid asset reserves at 75.44% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Viking Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Viking Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Genfit S.A.
PA:GNFT |
Biotechnology | 64.01% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 22.98% |
|
Altimmune Inc
NASDAQ:ALT |
Biotechnology | 82.06% |
|
Clarity Pharmaceuticals Ltd
AU:CU6 |
Biotechnology | 73.99% |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670 |
Biotechnology | 9.82% |
Annual Asset Resilience Ratio for Viking Therapeutics Inc (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Viking Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 75.44% | $539.93 Million | $715.73 Million | -21.00pp |
| 2024-12-31 | 96.43% | $875.94 Million | $908.32 Million | +13.24pp |
| 2023-12-31 | 83.19% | $306.56 Million | $368.49 Million | +12.67pp |
| 2022-12-31 | 70.52% | $118.85 Million | $168.53 Million | -12.90pp |
| 2021-12-31 | 83.42% | $175.73 Million | $210.66 Million | -2.07pp |
| 2020-12-31 | 85.48% | $219.27 Million | $256.50 Million | -8.54pp |
| 2019-12-31 | 94.02% | $267.26 Million | $284.26 Million | +2.48pp |
| 2018-12-31 | 91.54% | $276.74 Million | $302.31 Million | +39.16pp |
| 2017-12-31 | 52.38% | $11.59 Million | $22.12 Million | -16.93pp |
| 2016-12-31 | 69.31% | $10.08 Million | $14.54 Million | -17.06pp |
| 2015-12-31 | 86.37% | $13.34 Million | $15.44 Million | -- |
About Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steato… Read more